Back to User profile » Dr Keng-Liang Wu
Papers published by Dr Keng-Liang Wu:
A Comparison Between Dexlansoprazole Modified Release–Based And Lansoprazole-Based Nonbismuth Quadruple (Concomitant) Therapy For First-Line Helicobacter pylori Eradication: A Prospective Randomized Trial [Corrigendum]
Tai WC, Liang CM, Bi KW, Kuo CM, Lu LS, Wu CK, Yang SC, Kuo YH, Lee CH, Huang CF, Hsu CN, Hsu PI, Wu DC, Hu TH, Wu KL, Chuah SK
Infection and Drug Resistance 2019, 12:3049-3050
Published Date: 25 September 2019
A comparison between dexlansoprazole modified release–based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial
Tai WC, Liang CM, Bi KW, Kuo CM, Lu LS, Wu CK, Yang SC, Kuo YH, Lee CH, Huang CF, Hsu CN, Hsu PI, Wu DC, Hu TH, Wu KL, Chuah SK
Infection and Drug Resistance 2019, 12:2923-2931
Published Date: 16 September 2019
First-line Helicobacter pylori eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus
Yao CC, Kuo CM, Hsu CN, Yang SC, Wu CK, Tai WC, Liang CM, Wu KL, Huang CF, Bi KW, Lee CH, Chuah SK
Infection and Drug Resistance 2019, 12:1425-1431
Published Date: 29 May 2019
Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial
Chiang HH, Wu DC, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Yao CC, Tsai CE, Liang CM, Wang YK, Wang JW, Huang CF, Chuah SK
Drug Design, Development and Therapy 2019, 13:1347-1356
Published Date: 26 April 2019
Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication
Huang HT, Wang HM, Yang SC, Tai WC, Liang CM, Wu KL, Lee CH, Chuah SK
Infection and Drug Resistance 2018, 11:2073-2080
Published Date: 30 October 2018